Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Ho

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Blood|September 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Nature Communications|May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Blood|September 12, 2022
Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significanceMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
American Journal of Hematology|October 13, 2022
Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosisMatthew Ho, Saurabh Zanwar, Francis K Buadi, et al.
Nature Communications|May 15, 2026
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapyMichael Schneider, Luca Paruzzo, Federico Stella, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Pageof 8